Lucy To - 03 Feb 2026 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role
Chief Financial Officer
Signature
/s/ Lucy To
Issuer symbol
SABS
Transactions as of
03 Feb 2026
Net transactions value
$0
Form type
4
Filing time
05 Feb 2026, 16:35:02 UTC
Previous filing
28 Aug 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
To Lucy Chief Financial Officer 777 W 41ST STREET, SUITE 401, MIAMI BEACH /s/ Lucy To 05 Feb 2026 0002032049

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SABS Stock option (right to buy) Award $0 +2,400,000 $0.000000 2,400,000 03 Feb 2026 Common Stock 2,400,000 $4.45 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents options to purchase shares of the Issuer's common stock par value $0.0001 per share, pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
F2 The shares underlying the option vest over a four-year period, vesting 1/4 on the one-year anniversary of the date of grant, and the remaining 3/4 vesting pro rata on a monthly basis in 36 equal installments thereafter.

Remarks:

Chief Financial Officer